Cite
Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.
MLA
Rodriguez, Cristina P., et al. “Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.” JNCI: Journal of the National Cancer Institute, vol. 114, no. 12, Dec. 2022, pp. 1619–27. EBSCOhost, https://doi.org/10.1093/jnci/djac163.
APA
Rodriguez, C. P., Kang, H., Geiger, J. L., Burtness, B., Chung, C. H., Pickering, C. R., Fakhry, C., Le, Q. T., Yom, S. S., Galloway, T. J., Golemis, E., Li, A., Shoop, J., Wong, S., Mehra, R., Skinner, H., Saba, N. F., Flores, E. R., Myers, J. N., & Ford, J. M. (2022). Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. JNCI: Journal of the National Cancer Institute, 114(12), 1619–1627. https://doi.org/10.1093/jnci/djac163
Chicago
Rodriguez, Cristina P, Hyunseok Kang, Jessica L Geiger, Barbara Burtness, Christine H Chung, Curtis R Pickering, Carole Fakhry, et al. 2022. “Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.” JNCI: Journal of the National Cancer Institute 114 (12): 1619–27. doi:10.1093/jnci/djac163.